Acute Left Ventricular Dysfunction Following Gemtuzumab Ozogamicin in Two Pediatric AML Patients

Kevin O. McNerney; Katelyn Oranges; Alix E. Seif; Benjamin Oshrine; Bonnie Ky; Kimberly Y. Lin; Kelly D. Getz; Richard Aplenc

doi:10.1097/MPH.0000000000002325

Acute Left Ventricular Dysfunction Following Gemtuzumab Ozogamicin in Two Pediatric AML Patients

Kevin O. McNerney, Katelyn Oranges, Alix E. Seif, Benjamin Oshrine, Bonnie Ky, Kimberly Y. Lin, Kelly D. Getz, Richard Aplenc^*

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article › peer-review

Abstract

Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody-tumor antibiotic conjugate with proven efficacy in pediatric and adult patients with CD33⁺acute myeloid leukemia. Adverse effects commonly associated with GO include hyperbilirubinemia, elevated transaminases, and sinusoidal obstruction syndrome. Cardiotoxicity has not been a commonly described adverse event. We describe 2 pediatric patients with relapsed/refractory acute myeloid leukemia who received fractionated GO monotherapy and subsequently developed severe acute left ventricular dysfunction. Both patients achieved remission, recovered cardiac function with medical therapy, and tolerated subsequent stem cell transplantation.

Original language	English (US)
Pages (from-to)	E507-E511
Journal	Journal of pediatric hematology/oncology
Volume	44
Issue number	2
DOIs	https://doi.org/10.1097/MPH.0000000000002325
State	Published - Mar 1 2022

Keywords

acute myeloid leukemia
cardio-oncology
cardiotoxicity
gemtuzumab ozogamicin

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1097/MPH.0000000000002325

Cite this

@article{8dd85afd85484cbd95b95a881e0cf11c,

title = "Acute Left Ventricular Dysfunction Following Gemtuzumab Ozogamicin in Two Pediatric AML Patients",

abstract = "Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody-tumor antibiotic conjugate with proven efficacy in pediatric and adult patients with CD33+acute myeloid leukemia. Adverse effects commonly associated with GO include hyperbilirubinemia, elevated transaminases, and sinusoidal obstruction syndrome. Cardiotoxicity has not been a commonly described adverse event. We describe 2 pediatric patients with relapsed/refractory acute myeloid leukemia who received fractionated GO monotherapy and subsequently developed severe acute left ventricular dysfunction. Both patients achieved remission, recovered cardiac function with medical therapy, and tolerated subsequent stem cell transplantation.",

keywords = "acute myeloid leukemia, cardio-oncology, cardiotoxicity, gemtuzumab ozogamicin",

author = "McNerney, {Kevin O.} and Katelyn Oranges and Seif, {Alix E.} and Benjamin Oshrine and Bonnie Ky and Lin, {Kimberly Y.} and Getz, {Kelly D.} and Richard Aplenc",

year = "2022",

month = mar,

day = "1",

doi = "10.1097/MPH.0000000000002325",

language = "English (US)",

volume = "44",

pages = "E507--E511",

journal = "Journal of Pediatric Hematology/Oncology",

issn = "1077-4114",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Acute Left Ventricular Dysfunction Following Gemtuzumab Ozogamicin in Two Pediatric AML Patients

AU - McNerney, Kevin O.

AU - Oranges, Katelyn

AU - Seif, Alix E.

AU - Oshrine, Benjamin

AU - Ky, Bonnie

AU - Lin, Kimberly Y.

AU - Getz, Kelly D.

AU - Aplenc, Richard

PY - 2022/3/1

Y1 - 2022/3/1

N2 - Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody-tumor antibiotic conjugate with proven efficacy in pediatric and adult patients with CD33+acute myeloid leukemia. Adverse effects commonly associated with GO include hyperbilirubinemia, elevated transaminases, and sinusoidal obstruction syndrome. Cardiotoxicity has not been a commonly described adverse event. We describe 2 pediatric patients with relapsed/refractory acute myeloid leukemia who received fractionated GO monotherapy and subsequently developed severe acute left ventricular dysfunction. Both patients achieved remission, recovered cardiac function with medical therapy, and tolerated subsequent stem cell transplantation.

AB - Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody-tumor antibiotic conjugate with proven efficacy in pediatric and adult patients with CD33+acute myeloid leukemia. Adverse effects commonly associated with GO include hyperbilirubinemia, elevated transaminases, and sinusoidal obstruction syndrome. Cardiotoxicity has not been a commonly described adverse event. We describe 2 pediatric patients with relapsed/refractory acute myeloid leukemia who received fractionated GO monotherapy and subsequently developed severe acute left ventricular dysfunction. Both patients achieved remission, recovered cardiac function with medical therapy, and tolerated subsequent stem cell transplantation.

KW - acute myeloid leukemia

KW - cardio-oncology

KW - cardiotoxicity

KW - gemtuzumab ozogamicin

UR - http://www.scopus.com/inward/record.url?scp=85117936076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85117936076&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000002325

DO - 10.1097/MPH.0000000000002325

M3 - Article

C2 - 35200224

AN - SCOPUS:85117936076

SN - 1077-4114

VL - 44

SP - E507-E511

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

IS - 2

ER -

Acute Left Ventricular Dysfunction Following Gemtuzumab Ozogamicin in Two Pediatric AML Patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this